Value Sense
BLTE
Belite Bio, Inc (BLTE)
Last Price$68.62.5%
Market Cap$2,075.9M
LTM EPS
($1.1)
YoY Growth
-100.0%
3Y CAGR
+4.6%
5Y CAGR
+56.0%
Stock quality & Intrinsic value
5/10
76.6% overvalued
BLTE
is (76.6%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Belite Bio, Inc EPS

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'20Dec'21Dec'22Dec'23
EPS
($0.2)
($0.4)
($0.6)
($1.2)
BLTE
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for BLTE and see if it's the right time to invest.
Dive in

Belite Bio, Inc (BLTE) EPS comparison analysis

General

LTM EPS

Growth

Company name

YoY growth

3Y CAGR

5Y CAGR

Belite Bio, Inc logo
Belite Bio, IncBLTE
($1.1)
(100.0%)
4.6%
N/A
Median Peer Set
($1.0)
0.0%
0.0%
0.0%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
$40.9
10.3%
(18.8%)
16.1%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
$26.5
25.6%
35.7%
N/A
Royalty Pharma plc logo
Royalty Pharma plcRPRX
$2.3
(9.0%)
15.1%
(19.0%)
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
$2.3
152.8%
N/A
N/A
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
($0.3)
(92.8%)
(31.4%)
(0.9%)
argenx SE logo
argenx SEARGX
($1.8)
(57.5%)
N/A
(9.7%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
($2.1)
N/A
N/A
N/A
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
($2.2)
(38.5%)
(33.0%)
(23.2%)
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
($3.3)
20.9%
45.1%
25.3%
BioNTech SE logo
BioNTech SEBNTX
($4.2)
N/A
N/A
36.5%

BLTE key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
Cost of Goods Sold (COGS)0.00.00.20.4
Gross Profit
% margin
(0.0)
0.0%
(0.0)
0.0%
(0.2)
0.0%
(0.4)
0.0%
Operating Expenses5.79.812.831.7
Research & Development Expenses (R&D)3.77.48.924.8
Selling, General & Administrative Expenses (SG&A)2.12.44.06.8
Operating Income
% margin
(5.7)
0.0%
(9.8)
0.0%
(12.8)
0.0%
(31.7)
0.0%
Interest Income0.00.00.00.1
Interest Expense0.00.00.00.0
Pre-tax Income(5.8)(9.7)(12.6)(31.6)
Income Tax
% effective tax rate
0.0
(0.0%)
0.1
(1.3%)
(0.2)
1.4%
0.0
(0.0%)
Net Income
% margin
(5.8)
0.0%
(9.8)
0.0%
(12.5)
0.0%
(31.6)
0.0%
EPS(0.24)(0.41)(0.62)(1.19)
Diluted EPS(0.24)(0.41)(0.62)(1.19)
EBITDA
% margin
(5.7)
0.0%
(9.6)
0.0%
(12.4)
0.0%
(31.5)
0.0%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Belite Bio, Inc's EPS?

As of today, Belite Bio, Inc's last 12-month EPS is ($1.1), based on the financial report for Sep 30, 2024 (Q3’2024).

2) What is Belite Bio, Inc's EPS growth rate?

Over the last year, Belite Bio, Inc's EPS growth was (100.0%). The average annual EPS growth rates for Belite Bio, Inc have been 12.0% over the past three years, 56.0% over the past five years.

3) Is Belite Bio, Inc's EPS growth rate Good?

Over the last year, Belite Bio, Inc's EPS growth was (100.0%), which is lower than industry growth of (0.2%). It indicates that Belite Bio, Inc's EPS growth is Bad.